Cobo AC, Fabián MG, Narváez O

Language: Spanish
References: 14
Page: 106-109
PDF size: 74.48 Kb.

ABSTRACT

Chronic Congestive Heart Failure has a great morbility and mortality. Thirty three percent of patients died in the first year and the mortality in the next 5 years of the diagnosis is expected around 50%. Nesiritide is the first member of this new class of drugs, that is identical to the human natriuretic peptide type B, this is made by an advance technology using the recombinant form of DNA of the E coli. This molecule was discovered in 1988, and approved by the FDA in 2001, Since that year nesiritide was on the market in USA and was used in more than 300 thousand patients. The indication are congestive heart failure in patients with dyspnea with minimal effort. Nesiritide was used only for iv route. Different studies showed very fast relief of dyspnea and a reduction of pulmonary capillary wedge pressure. Recent papers described an increase of renal failure and mortality with the use of this drug, prospective studies with nesiritide do not show this, at the opposite nesiritide have a good profile, safety and reduce the days in the hospital without increase of mortality.

REFERENCES

1. Bonow RO. New insights into the cardiac natriuretic peptides. Circulation 1996; 93: 1946-1950.

2. Krumholz HM , Chen YT, Vaccarino V et al. Correlates and impact on outcomes of worsening renal failure in patients › 65 years of age with heart failure. Am J Cardiol 2002; 85: 1110-1113.

3. Gottlieb SS, Abraham W, Butler J. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002; 8: 136-141.

4. Lee DS, Austin PC, Rouleau JL et al. Predicting mortality among patients hospitalized for heart failure: deviation and validation of a clinical model. JAMA 2003; 290: 2581-2587.

5. Krunholz HM, Parent EN, Tu N et al. Readmission after hospitalization for congestive heart failure among medicare beneficiaries. Arch Intern Med 1997; 157: 99-106.

6. Yancy CW, Saltzberg MT, Berkowitz RI et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 2004; 94: 595-601.

7. Peacock WF, Holland R, Gyarmathy R et al. Safety and efficacy of nesiritide in observation patients - The PROACTION trial. J Am Coll Cardiol 2003; 1027: 87-93.

8. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated heart failure. JAMA 2002; 287: 1531-1540.

9. Burger AJ, Horton DP, LeJemtel T et al. Effect of nesiritide (B-Type Natriuretic Peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated CHF: The PRECEDENT study. Am Heart J 2002; 144: 1102-11088.

10. Colucci, WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. New Engl J Med 2000; 343: 246-253.

11. Mills RM, TH L, Horton D. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure. J Am Coll Card 1999; 34: 155-162.

12. Sackner-Bernstein J, Skopicki H, Aaronson K et al. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-1491.

13. Sackner-Bernstein J, Kowalsi M, Fox M et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure. JAMA 2005; 293: 1900-1905.

14. Topol E. Nesiritide-Not verified. New Engl J Med 2005; 353: 113-116.